Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBIT: 2009-2024

Historic EBIT for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to -$40.7 million.

  • Vanda Pharmaceuticals' EBIT fell 184.40% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.1 million, marking a year-over-year decrease of 223.13%. This contributed to the annual value of -$40.7 million for FY2024, which is 191.43% down from last year.
  • As of FY2024, Vanda Pharmaceuticals' EBIT stood at -$40.7 million, which was down 191.43% from -$14.0 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' EBIT registered a high of $42.2 million during FY2021, and its lowest value of -$40.7 million during FY2024.
  • In the last 3 years, Vanda Pharmaceuticals' EBIT had a median value of -$14.0 million in 2023 and averaged -$16.1 million.
  • In the last 5 years, Vanda Pharmaceuticals' EBIT soared by 54.80% in 2021 and then plummeted by 320.45% in 2023.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' EBIT stood at $27.2 million in 2020, then spiked by 54.80% to $42.2 million in 2021, then tumbled by 84.99% to $6.3 million in 2022, then slumped by 320.45% to -$14.0 million in 2023, then crashed by 191.43% to -$40.7 million in 2024.